Statutory Instruments
2025 No. 317
MEDICINES
FEES AND CHARGES
The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025
Made
at 10.02 a.m. on 11th March 2025
Laid before Parliament
at 4.00 p.m. on 11th March 2025
Laid before the Northern Ireland Assembly
at 4.00 p.m. on 11th March 2025
Coming into force
1st April 2025
The Secretary of State in relation to England and Wales and Scotland, and the Department of Health in Northern Ireland and the Secretary of State acting jointly in relation to Northern Ireland, make these Regulations in exercise of the powers conferred by section 2(1), 6(1)(a) and 43(2) of the Medicines and Medical Devices Act 2021(1).
The Secretary of State and the Department of Health in Northern Ireland have carried out a public consultation in accordance with section 45(1) of that Act.
In accordance with section 2(2) to (4) of that Act, the Secretary of Stateβs and the Department of Health in Northern Irelandβs overarching objective in making these Regulations is safeguarding public health, and the Secretary of State and the Department of Health in Northern Ireland have had regard to the matters specified in section 2(3) of that Act and consider that, where these Regulations may have an impact on the safety of human medicines, the benefits of making these Regulations outweigh the risks.
Citation, commencement and extent
1.β(1) These Regulations may be cited as the Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025.
(2) These Regulations come into force on 1st April 2025.
(3) These Regulations extend to England and Wales, Scotland and Northern Ireland.
Amendment of the Medicines (Products for Human Use) (Fees) Regulations 2016
2.The Medicines (Products for Human Use) (Fees) Regulations 2016(2) are amended in accordance with regulations 3 to 31.
New regulation 3A
3. After regulation 3 (interpretation of Part 2), insertβ
βFee for scientific or other advice
3A.β(1)Unless regulation 5 applies, the fee specified in paragraph (2) is payable by a person with whom the licensing authority holds a meeting in order to provide scientific or other advice relating to a medicinal product.
(2)The fee payable by a person in relation to a meeting referred to in paragraph (1) isβ
(a)Β£17,516, if the advice provided at that meeting is on a matter of high complexity;
(b)Β£13,137, if the advice provided at that meeting is on a matter of medium complexity;
(c)Β£8,758, if the advice provided at that meeting is on a matter of low complexity;
(d)Β£986, if the advice provided at that meeting is on a matter of simple complexity.
(3)In paragraph (2), a matter is ofβ
(a)high complexity if it requires more than twelve assessor days;
(b)medium complexity if it requires more than seven, but not more than twelve, assessor days;
(c)low complexity if it requires more than three, but not more than seven, assessor days;
(d)simple complexity if it requires not more than three assessor days.
(4)If the person paying the fee in accordance with paragraph (1) consents, the licensing authority may provide any advice in writing instead of at a meeting.
(5)In this regulationβ
βassessor dayβ meansβ
in the case of an assessor who is a member of the senior civil service, one assessor working for one day;
in the case of an assessor who is not a member of the senior civil service, one assessor working for two days.
βmedicinal productβ, in paragraph (e) of the definition of scientific or other advice in this regulation, includes a substance incorporated in a device which, if used separately, may be considered to be a medicinal product as defined in Article 1(2) of the 2001 Directive;
βscientific or other adviceβ includesβ
scientific advice on an application for an EU marketing authorisation, or an application for the variation of an EU marketing authorisation, in relation to a medicinal product;
advice before the publication of advertising of a medicinal product by the holder of a marketing authorisation for that product on whether that advertising conforms to the requirements of the Human Medicines Regulations;
pharmacovigilance advice;
regulatory advice;
advice in relation toβ
scientific or regulatory issues relating to the development of a medicinal product or a type of medicinal product;
the design of pharmaceutical or pre-clinical tests, or clinical trials, for a medicinal product or a type of medicinal product;
the management of risk in relation to a medicinal product or a type of medicinal product which is under development, or is being marketed;
other scientific or regulatory issues relating to a medicinal product or a type of medicinal product after an EU marketing authorisation has been granted for that product or a product of that type.β.
Omission of regulation 4
4. Omit regulation 4 (fee for scientific advice: application for, or variation to, EU marketing authorisation)(3).
Amendment of regulation 5
5. In regulation 5(1) (fee for scientific advice: classification of a medicinal product)(4)β
(a)in sub-paragraph (a), for βΒ£3,039β substitute βΒ£8,758β;
(b)in sub-paragraph (b), for βΒ£3,986β substitute βΒ£8,758β.
Omission of regulation 6
6. Omit regulation 6 (fee for advertising advice)(5).
Omission of regulation 7
7. Omit regulation 7 (fee for pharmacovigilance advice)(6).
Amendment of regulation 8
8. In regulation 8 (fee for advice on labelling or leaflets)(7), for βΒ£2,421β substitute βΒ£3,757β.
Omission of regulation 9
9. Omit regulation 9 (fee for regulatory advice)(8).
Omission of regulation 10
10. Omit regulation 10 (fee for advice for other purposes)(9).
Amendment of regulation 10A
11. In regulation 10A(1) (waiver for advice given to small and medium companies)(10), for β4 to 10β substitute β3A to 8β.
Amendment of regulation 11
12. In regulation 11 (time for payment of fees under regulations 4 to 10), for β4 to 10β, in each place it occurs (including the heading to the regulation), substitute β3A to 8β.
Amendment of regulation 14
13. In regulation 14 (fee for applications for additional copy certificates)(11), for βΒ£75β substitute βΒ£82β.
Amendment of regulation 15
14. In regulation 15 (fees for applications for certificates and copy certificates by exporters of medicinal products)(12)β
(a)in paragraph (1)(a), for βΒ£167β substitute βΒ£182β;
(b)in paragraph (1)(b), for βΒ£75β substitute βΒ£82β.
Amendment of regulation 19A
15. In regulation 19A (fees for certification of plasma master files)(13)β
(a)in paragraph (1), for βΒ£9,140β substitute βΒ£11,126β;
(b)in paragraph (2)(a), for βΒ£344β substitute βΒ£419β;
(c)in paragraph (2)(b), for βΒ£1,308β substitute βΒ£1,593β.
Amendment of regulation 19B
16. In regulation 19B (fee for certification of vaccine antigen master files)(14), for βΒ£9,140β substitute βΒ£11,126β.
Amendment of regulation 19C
17. In regulation 19C (fees for assessment of post-authorisation safety studies)(15) for βΒ£9,140β, in both places it occurs, substitute βΒ£9,949β.
Amendment of regulation 19E
18. In regulation 19E(2) (fee for assessment of periodic safety update reports)(16)β
(a)in sub-paragraph (a), for βΒ£979β substitute βΒ£1,066β;
(b)in sub-paragraph (b), for βΒ£490β substitute βΒ£534β.
Amendment of regulation 19EA
19. In regulation 19EA (fee for assessment of clinical trial annual safety reports)(17), for βΒ£248β substitute βΒ£343β.
Amendment of regulation 21
20. In regulation 21(1) (fees for notification of changes and reports for brokerβs registrations)(18), for βΒ£283β substitute βΒ£345β.
Amendment of regulation 22
21. In regulation 22(1) (fees for notification of changes and compliance reports for active substance registrations)(19), for βΒ£283β substitute βΒ£309β.
Amendment of regulation 27
22. In regulation 27(1) (fees for renewals of certain manufacturerβs licences)(20), for βΒ£196β substitute βΒ£214β.
Amendment of regulation 41
23. In regulation 41 (fees for applications for membership and certificates)(21)β
(a)in paragraph (1), for βΒ£129β substitute βΒ£141β;
(b)in paragraph (2), for βΒ£68β substitute βΒ£75β.
Amendment of regulation 42
24. In regulation 42(1) (fee for a review upon oral representations or a person appointed hearing)(22), for βΒ£11,000β substitute βΒ£11,974β.
Amendment of regulation 44
25. In regulation 44(1) (interpretation), in the definition of βstandard variationββ
(a)in sub-paragraph (o), at the end, omit βorβ;
(b)in sub-paragraph (p), for βauthorisation.β substitute βauthorisation; orβ;
(c)after sub-paragraph (p), insertβ
β(q)a change to any packaging of the product, including the container or other form of packaging immediately in contact with the medicinal product, any packaging into which the container or other form of packaging immediately in contact with the product is placed, or to a leaflet that accompanies the product and contains information for the user of the product.β.
Amendment of regulation 47
26. In regulation 47 (fees for variations of certificates)β
(a)in paragraph (1)(a)β
(i)in paragraph (i), for βΒ£123β substitute βΒ£149β;
(ii)in paragraph (ii), for βΒ£62β substitute βΒ£75β;
(b)in paragraph (1)(b), for βΒ£123β substitute βΒ£149β;
(c)in paragraph (2)(a)β
(i)in paragraph (i), for βΒ£243β substitute βΒ£296β;
(ii)in paragraph (ii), for βΒ£243β substitute βΒ£296β;
(iii)in paragraph (iii), for βΒ£123β substitute βΒ£149β;
(iv)in paragraph (iv), for βΒ£62β substitute βΒ£75β;
(d)in paragraph (2)(b), for βΒ£243β substitute βΒ£296β.
Amendment of Schedule 2
27.β(1)Schedule 2 (capital fees for applications for, and variations to, marketing authorisations, licences, registrations and certificates) is amended as follows.
(2) In paragraph 21 (standard variation application for a homoeopathic medicinal product)β
(a)in sub-paragraph (o), at the end, omit βorβ;
(b)in sub-paragraph (p), for βDirective.β substitute βDirective; orβ;
(c)after sub-paragraph (p), insertβ
β(q)a change to any packaging of the product, including the container or other form of packaging immediately in contact with the medicinal product, any packaging into which the container or other form of packaging immediately in contact with the product is placed, or to a leaflet that accompanies the product and contains information for the user of the product.β.
(3) In paragraph 24(5) (marketing authorisations)(23), in the table (fees for marketing authorisation applications)β
(a)in item 1 (major application)β
(i)in entry (a), for βΒ£32,705β substitute βΒ£39,811β;
(ii)in entries (b) to (d), for βΒ£68,663β, in each place it occurs, substitute βΒ£83,580β;
(iii)in entry (e), for βΒ£20,281β substitute βΒ£24,688β;
(iv)omit entry (f);
(v)omit entry (g);
(vi)in entry (h), for βΒ£102,028β substitute βΒ£124,194β;
(b)in item 2 (complex application)β
(i)in entries (a) to (c), for βΒ£19,063β, in each place it occurs, substitute βΒ£23,205β;
(ii)in entry (d), for βΒ£11,487β substitute βΒ£13,983β;
(iii)omit entry (e);
(iv)omit entry (f);
(v)in entry (g), for βΒ£28,207β substitute βΒ£34,335β;
(c)in item 3 (standard application)β
(i)in entries (a) to (c), for βΒ£6,985β, in each place it occurs, substitute βΒ£8,503β;
(ii)in entry (d), for βΒ£6,361β substitute βΒ£7,743β;
(iii)omit entry (e);
(iv)omit entry (f);
(v)in entry (g), for βΒ£10,342β substitute βΒ£12,589β;
(d)in item 4 (simple application)β
(i)in entries (a) to (c), for βΒ£2,820β, in each place it occurs, substitute βΒ£3,433β;
(ii)omit entry (d);
(iii)omit entry (e);
(iv)in entry (f), for βΒ£2,820β substitute βΒ£3,433β;
(e)in item 5 (parallel import licence applications)β
(i)in entry (a), for βΒ£1,971β substitute βΒ£2,400β;
(ii)in entry (b), for βΒ£8,722β substitute βΒ£10,617β;
(iii)in entry (c), for βΒ£19,998β substitute βΒ£24,343β;
(f)in item 6 (change of ownership application), for βΒ£486β substitute βΒ£592β.
(4) In paragraph 25(1) (fees where application includes reclassification)(24)β
(a)in sub-paragraph (a), for βΒ£33,003β substitute βΒ£40,173β;
(b)in sub-paragraph (b), for βΒ£8,978β substitute βΒ£10,929β.
(5) In paragraph 28(4)(b) (application for multiple authorisations)(25), for βΒ£1,308β substitute βΒ£1,593β.
(6) In paragraph 28A (application by pre-assessment of modules)(26)β
(a)in sub-paragraphs (1)(a) to (c), for βΒ£25,507β, in each place it occurs, substitute βΒ£31,049β;
(b)in sub-paragraphs (2)(a) to (c), for βΒ£4,766β, in each place it occurs, substitute βΒ£5,802β.
(7) In paragraph 29 (authorisation for a national homoeopathic product)β
(a)in sub-paragraph (4), in the table (fees for homoeopathic marketing authorisation applications)β
(i)in the second column (fee for applications in respect of products prepared from not more than 5 homoeopathic stocks)β
(aa)in entry 1, for βΒ£517β substitute βΒ£630β;
(bb)in entry 2, for βΒ£808β substitute βΒ£984β;
(cc)in entry 3, for βΒ£1,088β substitute βΒ£1,325β;
(ii)in the third column (fee for other applications)β
(aa)in entry 1, for βΒ£732β substitute βΒ£892β;
(bb)in entry 2, for βΒ£1,014β substitute βΒ£1,235β;
(cc)in entry 3, for βΒ£1,312β substitute βΒ£1,598β;
(b)in sub-paragraph (6), for βΒ£2,154β substitute βΒ£2,622β;
(c)in sub-paragraph (7), for βΒ£7,185β substitute βΒ£8,746β;
(d)in sub-paragraph (8), for βΒ£635β substitute βΒ£773β.
(8) In paragraph 30(1) (manufacturerβs licences and authorisations)(27)β
(a)in sub-paragraph (a), for βΒ£201β substitute βΒ£245β;
(b)in sub-paragraph (b), for βΒ£378β substitute βΒ£461β;
(c)in sub-paragraph (c), for βΒ£3,457β substitute βΒ£4,209β.
(9) In paragraph 31 (wholesale dealerβs licences)(28)β
(a)in sub-paragraph (1), for βΒ£1,983β substitute βΒ£2,159β;
(b)in sub-paragraph (5), for βΒ£439β substitute βΒ£478β.
(10) In paragraph 33(1) (active substance registrations)(29)β
(a)in paragraph (a), for βΒ£3,457β substitute βΒ£3,763β;
(b)in paragraph (b), for βΒ£1,983β substitute βΒ£2,159β.
(11) In paragraph 34 (clinical trial authorisations)(30)β
(a)in sub-paragraph (a), for βΒ£3,366β substitute βΒ£4,656β;
(b)in sub-paragraph (b), for βΒ£248β substitute βΒ£343β.
(12) In paragraph 35 (traditional herbal registrations)(31)β
(a)in sub-paragraph (1), in the second column (fee payable) of the table (fee for application for traditional herbal registration)β
(i)in entry 1 (complex registration application)β
(aa)in entry (a), for βΒ£4,846β substitute βΒ£5,899β;
(bb)in entry (b), for βΒ£7,269β substitute βΒ£8,848β;
(ii)in entry 2 (standard registration application)β
(aa)in entry (a), for βΒ£2,423β substitute βΒ£2,950β;
(bb)in entry (b), for βΒ£3,634β substitute βΒ£4,424β;
(iii)in entry 3 (reduced registration application category II)β
(aa)in entry (a), for βΒ£807β substitute βΒ£983β;
(bb)in entry (b), for βΒ£1,212β substitute βΒ£1,476β;
(iv)in entry 4 (reduced registration application category I)β
(aa)in entry (a), for βΒ£539β substitute βΒ£657β;
(bb)in entry (b), for βΒ£807β substitute βΒ£983β;
(v)in entry 5 (change of ownership application), for βΒ£486β substitute βΒ£592β.
(b)in sub-paragraph (3)β
(i)in paragraph (a), for βΒ£1,077β substitute βΒ£1,311β;
(ii)in paragraph (b), for βΒ£2,154β substitute βΒ£2,622β;
(c)in sub-paragraph (4), for βΒ£7,186β substitute βΒ£8,748β;
(d)in sub-paragraph (5), for βΒ£638β substitute βΒ£777β;
(e)in sub-paragraph (6), for βΒ£2,154β substitute βΒ£2,622β.
(13) In paragraph 35A (early access to medicines scheme fees), in the second column (fee payable) of the table (fees for early access to medicines scheme applications)(32)β
(a)in entry 1, for βΒ£3,986β substitute βΒ£4,852β;
(b)in entry 2, for βΒ£25,643β substitute βΒ£31,214β;
(c)in entry 3, for βΒ£12,821β substitute βΒ£15,607β;
(d)in entry 4, for βΒ£8,309β substitute βΒ£10,115β;
(e)in entry 5, for βΒ£4,154β substitute βΒ£5,057β.
(14) In paragraph 38(6) (marketing authorisations)β
(a)in the second column (column 2 fee payable) of Table 1 (fees for applications for variations of marketing authorisations falling within the scope of Chapter II of Regulation (EC) No 1234/200833)β
(i)in item 1 (application for a single kind variation)β
(aa)in entries (a) and (b), for βΒ£344β, in both places it occurs, substitute βΒ£419β;
(bb)in entry (c), for βΒ£2,742β substitute βΒ£3,338β;
(cc)in entry (d), for βΒ£8,462β substitute βΒ£10,301β;
(ii)in item 2 (applications for a group)β
(aa)in entry (a), for βΒ£344β substitute βΒ£419β;
(bb)in entry (b), for βΒ£1,255β substitute βΒ£1,528β;
(cc)in entry (c), for βΒ£2,973β substitute βΒ£3,619β;
(dd)in entry (d), for βΒ£8,671β substitute βΒ£10,555β;
(b)in the second column (fee payable) of Table 2 (fees for applications for variations of marketing authorisations falling within the scope of Chapter IIa of Regulation (EC) No 1234/200834)β
(i)in item 1, for βΒ£344β substitute βΒ£419β;
(ii)in item 2, for βΒ£1,308β substitute βΒ£1,593β;
(iii)in item 3, for βΒ£9,140β substitute βΒ£11,126β;
(iv)in item 4, for βΒ£33,003β substitute βΒ£40,173β;
(v)in item 5, for βΒ£684β substitute βΒ£833β;
(vi)in item 6, for βΒ£1,817β substitute βΒ£2,212β;
(vii)in item 7, for βΒ£9,911β substitute βΒ£12,065β;
(viii)in item 8, for βΒ£28,904β substitute βΒ£35,184β;
(c)in the second column (fee payable) of Table 3 (fees for reclassification variation applications)(35)β
(i)in entry (a), for βΒ£33,003β substitute βΒ£40,173β;
(ii)in entry (b), for βΒ£8,978β substitute βΒ£10,929β.
(15) In paragraph 40(1) (reclassification of marketing authorisations)(36), for βΒ£1,308β substitute βΒ£1,593β.
(16) In paragraph 41 (variation of marketing authorisation: national homoeopathic products)β
(a)in sub-paragraph (a), for βΒ£243β substitute βΒ£296β;
(b)in sub-paragraph (b), for βΒ£374β substitute βΒ£456β;
(c)in sub-paragraph (c), for βΒ£123β substitute βΒ£149β.
(17) In paragraph 42(1) (variation of parallel import licence)(37)β
(a)in paragraph (a), for βΒ£33,003β substitute βΒ£40,173β;
(b)in paragraph (b), for βΒ£8,978β substitute βΒ£10,929β;
(c)in paragraph (c), for βΒ£393β substitute βΒ£479β.
(18) In paragraph 43 (manufacturerβs authorisations and licences)(38)β
(a)in sub-paragraph (a), for βΒ£283β substitute βΒ£345β;
(b)in sub-paragraph (b), for βΒ£565β substitute βΒ£688β.
(19) In paragraph 44 (variation of manufacturerβs authorisations and licences)(39), for βΒ£283β substitute βΒ£345β.
(20) In paragraph 45 (wholesale dealerβs licences)(40), for βΒ£535β substitute βΒ£652β.
(21) In paragraph 46 (variation of wholesale dealerβs licence)(41), for βΒ£283β substitute βΒ£345β.
(22) In paragraph 47 (variation of a brokerβs registration)(42), for βΒ£283β substitute βΒ£345β.
(23) In paragraph 48 (variation of an active substance registration)(43), for βΒ£283β substitute βΒ£309β.
(24) In paragraph 49(1) (clinical trial authorisations)(44), for βΒ£248β substitute βΒ£302β.
(25) In paragraph 50 (traditional herbal registrations)β
(a)in sub-paragraph (a), for βΒ£240β substitute βΒ£293β;
(b)in sub-paragraph (b), for βΒ£635β substitute βΒ£773β;
(c)in sub-paragraph (c), for βΒ£7,186β substitute βΒ£8,748β;
(d)in sub-paragraph (d), for βΒ£152β substitute βΒ£186β.
(26) In paragraph 54 (a set of changes)(45)β
(a)in sub-paragraph (1)β
(i)in paragraph (a), for βΒ£570β substitute βΒ£992β;
(ii)in paragraph (b), for βΒ£361β substitute βΒ£440β;
(b)in sub-paragraph (2), for βΒ£205β substitute βΒ£224β.
(27) In paragraph 56 (renewal of a marketing authorisation)(46)β
(a)in sub-paragraphs (a) and (b), for βΒ£822β, in both places it occurs, substitute βΒ£1,239β;
(b)in sub-paragraph (c), for βΒ£10,650β substitute βΒ£16,042β.
(28) In paragraph 57(2) (renewal of multiple marketing authorisations)(47)β
(a)in paragraphs (a)(i) and (a)(ii), for βΒ£822β, in both places it occurs, substitute βΒ£1,239β;
(b)in paragraph (b)(i), for βΒ£10,650β substitute βΒ£16,042β.
(29) In paragraph 57A (capital fee for conducting a major safety review)(48)β
(a)in sub-paragraph (a), for βΒ£56,415β substitute βΒ£61,408β;
(b)in sub-paragraph (b), for βΒ£65,555β substitute βΒ£71,357β;
(c)in sub-paragraph (c), for βΒ£74,694β substitute βΒ£81,305β;
(d)in sub-paragraph (d), for βΒ£83,834β substitute βΒ£91,254β.
(30) For paragraph 57B (capital fee for testing of samples by the appropriate authority)(49) substituteβ
β57B.β(1)The fee payable under regulation 19F(1) in connection with the submission of a sample of a batch of a medicinal product is Β£5,093 for each day taken to examine the sample for testing, the appropriate documentation (as defined in regulation 60A of the Human Medicines Regulations) or both (as the case may be), and the fee payable is to be adjusted pro rata for each period taken of less than 1 day.
(2)In this paragraph, a βdayβ means a period of 8 hours and 30 minutes.β.
Amendment of Schedule 3
28.β(1)Schedule 3 (fees for inspections) is amended as follows.
(2) In paragraph 2(1) (fees: general)(50)β
(a)in paragraph (1)(a), for βΒ£3,651β substitute βΒ£5,251β;
(b)in paragraph (1)(b), for βΒ£1,825β substitute βΒ£2,625β.
(3) In paragraph 5 (wholesale dealerβs licence: general)(51)β
(a)in sub-paragraphs (a) and (b), for βΒ£2,662β, in both places it occurs, substitute βΒ£4,136β;
(b)in sub-paragraph (b), for βΒ£1,331β substitute βΒ£2,068β.
(4) In paragraph 6(2) (wholesale dealerβs licence: traditional herbal medicinal products)(52)β
(a)in paragraph (a), for βΒ£1,023β substitute βΒ£1,114β;
(b)in paragraphs (b) and (c), for βΒ£1,880β, in both places it occurs, substitute βΒ£2,047β.
(5) In paragraph 7(3) (wholesale dealerβs licences: inspection of short duration)(53), for βΒ£1,331β substitute βΒ£2,068β.
(6) In paragraph 8 (brokerβs registrations)(54)β
(a)in sub-paragraph (1)β
(i)in paragraphs (a) and (b), for βΒ£2,662β, in both places it occurs, substitute βΒ£3,241β;
(ii)in paragraph (b), for βΒ£1,331β substitute βΒ£1,621β;
(b)in sub-paragraph (3), for βΒ£640β substitute βΒ£780β.
(7) In paragraph 9 (active substance registrations)(55)β
(a)in sub-paragraph (1)(a)β
(i)in sub-paragraphs (i) and (ii), for βΒ£3,651β, in both places it occurs, substitute βΒ£3,975β;
(ii)in sub-paragraph (ii), for βΒ£1,825β substitute βΒ£1,988β;
(b)in sub-paragraph (1)(b)β
(i)in sub-paragraphs (i) and (ii), for βΒ£2,662β, in both places it occurs, substitute βΒ£2,898β;
(ii)in sub-paragraph (ii), for βΒ£1,331β substitute βΒ£1,449β;
(c)in sub-paragraph (3)β
(i)in paragraph (a), for βΒ£871β substitute βΒ£949β;
(ii)in paragraph (b), for βΒ£640β substitute βΒ£697β.
(8) In paragraph 10 (office-based inspections)(56)β
(a)in sub-paragraph (a), for βΒ£2,562β substitute βΒ£4,924β;
(b)in sub-paragraph (b), for βΒ£1,862β substitute βΒ£3,810β.
Amendment of Schedule 4
29.β(1)Schedule 4 (Periodic fees for licences) is amended as follows.
(2) In paragraph 5 (marketing authorisations)(57), in column 2 (fee payable) of the table (periodic fees for holding a marketing authorisation)β
(a)in entry 1, for βΒ£10,681β substitute βΒ£11,627β;
(b)in entry 2, for βΒ£338β substitute βΒ£368β;
(c)in entry 3(a), for βΒ£10,681β substitute βΒ£11,627β;
(d)in entry 3(b)(i), for βΒ£2,671β substitute βΒ£2,908β;
(e)in entry 3(b)(ii), for βΒ£1,332β substitute βΒ£1,450β;
(f)in entries 3(b)(iii), (c) and (d), for βΒ£338β, in each place it occurs, substitute βΒ£368β;
(g)in entries 3(e) to (h), for βΒ£84β, in each place it occurs, substitute βΒ£92β.
(3) In paragraph 6 (marketing authorisation: where Part 2 of the Act applies)(58), for βΒ£338β substitute βΒ£368β.
(4) In paragraph 7 (marketing authorisation: derivatives)(59)β
(a)in sub-paragraph (a), for βΒ£10,681β substitute βΒ£11,627β;
(b)in sub-paragraph (b), for βΒ£7,209β substitute βΒ£7,847β.
(5) In paragraph 11(1) and (2) (manufacturerβs licences or manufacturing authorisations)(60), for βΒ£515β, in both places it occurs, substitute βΒ£561β.
(6) In paragraph 12 (wholesale dealerβs licences)(61)β
(a)in sub-paragraph (1), for βΒ£317β substitute βΒ£346β;
(b)in sub-paragraph (2), for βΒ£189β substitute βΒ£206β.
(7) In paragraph 15(1)(b)(62) (additional amount for manufacturerβs licences and wholesale dealerβs licences which relate to special medicinal products)β
(a)for Table 1 (additional periodic fee in connection with notices for imported special medicinal products) substituteβ
βTable 1
Additional periodic fee in connection with notices for imported special medicinal products
Column 1 | Column 2 |
---|---|
Number of special import notices | Additional amount |
1 to 20 | Β£86 |
21 to 100 | Β£427 |
101 to 500 | Β£2,131 |
501 to 1,000 | Β£4,261 |
1,001 to 2,000 | Β£8,521 |
2,001 to 5,000 | Β£17,042 |
5,001 to 10,000 | Β£34,083 |
10,001 to 15,000 | Β£51,125 |
15,001 to 20,000 | Β£68,166 |
20,001 to 25,000 | Β£85,208 |
25,001 to 30,000 | Β£102,249 |
30,001 to 35,000 | Β£119,291 |
35,001 to 40,000 | Β£136,333 |
40,001 to 45,000 | Β£153,375 |
45,001 to 50,000 | Β£170,417 |
Each additional 5,000 above 50,000 | Β£170,417 plus Β£17,042 for each additional 5,000 special import noticesβ; |
(b)in the second column (additional amount) of Table 2 (Additional periodic fee in connection with the number of different special medicinal products notified for import)β
(i)in the entry β1 to 5β, for βΒ£100β substitute βΒ£122β;
(ii)in the entry β6 to 10β, for β200β substitute βΒ£244β;
(iii)in the entry β11 to 20β, for βΒ£400β substitute βΒ£487β;
(iv)in the entry β21 to 50β, for βΒ£1,000β substitute βΒ£1,218β;
(v)in the entry β51 to 100, for βΒ£2,000β substitute βΒ£2,435β;
(vi)in the entry β101 to 200β, for βΒ£4,000β substitute βΒ£,4,869β;
(vii)in the entry βFor each additional 100 special medicinal products notified for import above 200β, for βΒ£2,000β substitute βΒ£4,869 plus Β£2,435 for each additional 100 special medicinal products notified for importβ.
(8) In paragraph 16 (traditional herbal registrations)(63), for βΒ£84β substitute βΒ£92β.
Amendment of Schedule 5
30.β(1)Schedule 5 (fees for certificates of registration) is amended as follows.
(2) In the tableβ
(a)in the second column (fees for applications in respect of products prepared from not more than 5 homoeopathic stocks)β
(i)in item 1, for βΒ£159β substitute βΒ£194β;
(ii)in item 2, for βΒ£478β substitute βΒ£582β;
(iii)in item 3, for βΒ£501β substitute βΒ£610β;
(iv)in item 5, for βΒ£430β substitute βΒ£524β;
(v)in item 7, for βΒ£790β substitute βΒ£962β;
(b)in the third column (fees for other applications)β
(i)in item 1, for βΒ£393β substitute βΒ£479β;
(ii)in item 2, for βΒ£704β substitute βΒ£857β;
(iii)in item 3, for βΒ£638β substitute βΒ£777β;
(iv)in item 5, for βΒ£563β substitute βΒ£686β;
(v)in item 7 for βΒ£1,034β substitute βΒ£1,259β.
Amendment of Schedule 7
31.β(1)Schedule 7 (waiver, reduction or refund of capital fees) is amended as follows.
(2) In paragraph 11(1) (scientific advice: paediatric indications), for βregulation 4β substitute βregulation 3Aβ.
Signed by authority of the Secretary of State for Health and Social Care
Karin Smyth
Minister of State
Department of Health and Social Care
at 10.02 a.m. on 11th March 2025
Sealed with the Official Seal of the Department of Health in Northern Ireland
Cathy Harrison
A senior officer of the Department of Health in Northern Ireland
2021 c. 3. The powers in section 2(1) of the Medicines and Medical Devices Act 2021, and in the provisions that relate to it, are exerciseable by the βappropriate authorityβ. See section 2(6) of that Act, which contains the definition of βappropriate authorityβ that is relevant to the powers being exercised. See section 9 of that Act for the definition of βlaw relating to human medicinesβ for the purposes of section 2(1) of that Act, and section 6(4) of that Act for the definition of βhuman medicines provisionβ for the purposes of section 6(1)(a) of that Act.
S.I. 2016/190; relevant amending instruments are S.I. 2019/775 (as amended by S.I. 2020/1448) and S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2021/905 and 2023/314.
Inserted by S.I. 2019/775 (as amended by S.I. 2020/1488).
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Inserted by S.I. 2019/775 and amended by S.I. 2023/314.
Inserted by S.I. 2019/775 and amended by S.I. 2023/314.
Inserted by S.I. 2019/775 (as amended by S.I. 2020/1488) and amended by S.I. 2023/314.
Inserted by S.I. 2019/775 and amended by S.I. 2023/314.
Inserted by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Table inserted by S.I. 2019/775 and amended by S.I. 2020/1488 and S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Inserted by S.I. 2019/775 (as amended by S.I. 2020/1488) and amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Inserted by S.I. 2023/314.
Substituted by S.I. 2019/775 (as amended by S.I. 2020/1488) and amended by S.I. 2023/314.
Amended by S.I. 2019/775 (as amended by S.I. 2020/1488) and 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Substituted by S.I. 2019/775 (as amended by S.I. 2020/1488) and amended by S.I. 2023/314.
Substituted by S.I. 2019/775 (as amended by S.I. 2020/1488) and amended by S.I. 2023/314.
Inserted by S.I. 2019/775 and amended by S.I. 2023/314.
Inserted by S.I. 2019/775 and amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.
Amended by S.I. 2023/314.